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Abstract
AIM: To test the psychometric properties of a Chinese 
[(Hong Kong) HK] translation of the chronic liver disease 
questionnaire (CLDQ).
METHODS: A Chinese (HK) translation of the CLDQ 
was developed by iterative translation and cognitive 
debriefing. It was then administered to 72 uncom­
plicated and 78 complicated chronic hepatitis B (CHB) 
patients in Hong Kong together with a structured 
questionnaire on service utilization, and the Chinese (HK) 
SF­36 Health Survey Version 2 (SF­36v2).
RESULTS: Scaling success was ≥ 80% for all but three 
items. A new factor assessing sleep was found and items 
of two (Fatigue and Systemic Symptoms) subscales 
tended to load on the same factor. Internal consistency 
and test­retest reliabilities ranged from 0.58­0.90 for 
different subscales. Construct validity was confirmed 
by the expected correlations between the SF­36v2 
Health Survey and CLDQ scores. Mean scores of CLDQ 
were significantly lower in complicated compared with 
uncomplicated CHB, supporting sensitivity in detecting 
differences between groups.
CONCLUSION: The Chinese (HK) CLDQ is valid, 
reliable and sensitive for patients with CHB. Some modifi­
cations to the scaling structure might further improve its 
psychometric properties.
© 2009 The WJG Press and Baishideng. All rights reserved.
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INTRODUCTION
Chronic hepatitis B (CHB) virus infection remains a major 
global health problem. It is estimated that 350 million 
people worldwide are chronically infected, of  whom 
one third (120 million) are Chinese[1]. The prevalence is 
higher in southern China (> 10%) than Northern China 
(6%-10%)[2]. Up to 25% of  patients may die from CHB 
complications, such as cirrhosis-related complications or 
hepatocellular carcinoma (HCC), posing a threat to both 
mental and physical health, leading to impairment of  
health-related quality of  life (HRQOL).
HRQOL has become an important outcome mea-
sure in clinical and health policy settings in the last two 
decades. Disease-specific measures are often needed to 
complement generic measures to give a more comprehen-
sive evaluation of  the HRQOL of  patients with specific 
diseases. Several HRQOL measures have been developed 
specifically for chronic liver disease (CLD), such as the 
Chronic Liver Disease Questionnaire (CLDQ)[3], the Hep-
atitis Quality of  Life (HQLQ)[4], the Liver Disease Quality 
of  Life[5] and the Liver Disease Symptom Index (LDSI)[6]. 
The CLDQ developed by Younossi et al[3] was the first and 
is the most widely used. The other liver disease-specific 
HRQOL measures are not commonly used because they 
are either too long, or the validity data are limited[4-8].
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The CLDQ consists of  29 items which are grouped 
into 6 subscales: abdominal symptoms (AS), fatigue (FA), 
systemic symptoms (SS), activity (AC), emotional function 
(EF) and worry (WO). It is applicable to all types of  liver 
diseases including CHB. It has been shown to have ade-
quate internal reliability, validity and sensitivity. Test-retest 
reliability was more variable with intra-class correlation 
(ICC) ranging from 0.23 to 0.72 for different subscales[3]. 
Previous studies showed that the CLDQ is more respon-
sive than a generic measure to detect a change in patients 
with CLD[3,9]. It has been translated and validated in dif-
ferent languages[9-13], supporting its potential for cross-
cultural adaptation. However, most of  the psychometric 
data of  the CLDQ have been derived from patients with 
hepatitis C virus (HCV) infection and Western popula-
tions. There are few data on its applicability for Southern 
Chinese CHB patients despite the fact that China has the 
world’s largest population suffering from CLD.
Recently, the CLDQ has been translated into Manda-
rin Chinese but this Chinese (Mainland) version may not 
be applicable to Southern Chinese who speak Cantonese, 
a dialect that has significant differences in the usage of  
words and terms from Mandarin. In addition, information 
on the validity, reliability and other psychometric proper-
ties of  the Chinese (Mainland) CLDQ version is limited. 
The aim of  this study was to test the psychometric prop-
erties of  a Chinese [Hong Kong (HK)] translation of  the 
CLDQ for Southern Chinese CHB patients. This would 
enable the evaluation of  the impact of  CHB infection and 
assess the effect of  anti-viral drug treatments on HRQOL 
in the world’s largest population of  CHB patients.
The objectives of  this study were: (1) To develop a 
Chinese (HK) CLDQ that is semantically equivalent to 
the original; (2) To test the scaling assumptions and factor 
structure of  the Chinese (HK) CLDQ; (3) To assess the 
psychometric properties in terms of  reliability, construct 
validity, and sensitivity of  the Chinese (HK) CLDQ; (4) 
To determine whether any modification of  the CLDQ 
can improve its psychometric properties for Southern 
Chinese CHB patients.
MATERIALS AND METHODS
Ethics
This research project was approved by the Institutional 
Review Board of  the University of  Hong Kong/Hospital 
Authority Hong Kong West Cluster (IRB reference No., 
UW 06-089 T/1114 and trial registration No., HKC-
TR-151).
Development of the Chinese (HK) CLDQ
The Chinese (HK) translation of  the CLDQ was 
developed by iterative translations, expert panel review 
and cognitive debriefing, as recommended guidelines 
by experts[14,15]. The original CLDQ was translated into 
Chinese by two independent professional translators. 
Reconciliation of  the forward translations into a single 
forward translation was carried out by a bilingual expert 
in HRQOL measures (Lam CLK) and the translators. 
The reconciled Chinese translation was back-translated 
into English by another professional translator. The back 
translation was reviewed by the original author and the 
bilingual expert to identify any non-equivalence in the 
Chinese translation, which was then revised. The first draft 
of  the Chinese (HK) CLDQ was evaluated by cognitive 
debriefing interviews with six Southern Chinese patients 
with CHB infection and further revision was made to 
ensure item clarity and equivalence to become the final 
Chinese (HK) CLDQ (used in this study on psychometrics 
properties).
Subjects
Patients with complicated CHB were recruited from out-
patient hepatitis clinics of  a regional hospital and patients 
with uncomplicated CHB were randomly selected from the 
computerized registers of  three public primary care clinics 
serving over 100 000 people in one of  five regions in Hong 
Kong. Patients aged 18 years or older who were hepatitis 
B surface antigen-positive for more than six months were 
included in the study. Patients were excluded if  they could 
not communicate in Cantonese; had cognitive impairment 
shown by the patient’s inability to understand the study to 
give consent; were co-infected with HIV, HCV or hepa-
titis D virus; had undergone liver transplantation or had 
end-stage non-hepatitis B-related illnesses; were currently 
taking excessive alcohol (> 30 U/wk) or illegal drugs; 
or refused to give consent. Each patient completed the 
Chinese (HK) CLDQ, the Chinese (HK) SF-36v2 Health 
Survey and a structured questionnaire on morbidity and 
socio-demographics, administered by a trained interviewer. 
Each patient was asked if  he/she had ever been diagnosed 
by a registered practitioner for more than four weeks to 
have hypertension, diabetes mellitus, heart disease, stroke, 
chronic lung disease, arthritis, psychological illness (i.e. de-
pression, anxiety, neurasthenia or psychosis) or any other 
chronic diseases. Chronic co-morbidity was measured by 
the total number of  diseases (summation of  positive re-
sponses to the questions) and the presence of  a specific 
diagnosis. Clinical data related to the CHB infection in-
cluding Child’s staging for patients with cirrhosis and the 
biomarkers of  liver disease (alanine aminotransferase, as-
partate aminotransferase, α-fetoprotein and total bilirubin) 
in each patient were retrieved from medical records. Socio-
demographic data including age, gender, education, marital 
status, occupation, household income and family history 
of  liver disease were also collected.
The Chinese (HK) CLDQ was re-administered to the 
46 subjects with uncomplicated CHB, whose condition was 
expected to be stable, by telephone two weeks from the 
first administration, in order to assess the test-retest reliabil-
ity of  the Chinese (HK) CLDQ. Sixty one percent of  the 
repeat interviews were carried out by the same interviewer.
Instruments
The Chinese (HK) CLDQ consists of  29 i tems 
measuring six subscales as described above. Each item 
is rated on a 7-point (1 = all of  the time to 7 = none of  
the time) Likert scale. Scores for each of  the six domains 
are calculated by the mean of  the item scores within the 
subscale. A summary score is calculated by the mean of  
all subscale scores. The scores range from 1 to 7 with a 
higher score indicating better HRQOL.
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The Chinese (HK) SF-36v2 Health Survey is a generic 
HRQOL measure that has been translated, validated 
and normed on the general Chinese population in Hong 
Kong[16,17]. It measures eight domains of  HRQOL on 
physical functioning (PF), role-physical (RP), bodily pain 
(BP), general health (GH), vitality (VT), social functioning 
(SF), role-motional (RE) and mental health (MH). Sum-
mations of  item scores of  the same domain give the domain 
scores, which are transformed into a range from 0 to 100. 
A higher score indicates better HRQOL. The eight domain 
scores are summarized to form the physical component 
(PCS) and mental component (MCS) summary scores. 
Statistical analysis
All data analysis was carried out in SPSS for Windows 15.0. 
Statistical significant levels were set at P values less than 0.05.
Scaling assumptions
The CLDQ item and subscale scores were calculated and 
tested against the following scaling assumptions: (1) Items 
should be substantially linearly correlated to the hypoth-
esized subscale score with a coefficient of  0.4 or above 
by Spearman rank correlation test, to show the item is a 
significant indicator for the subscale concept. (2) An item 
should have a stronger correlation with its hypothesized 
subscale than other subscales indicating scaling success[18]. 
This is a test of  item discriminant validity. The difference 
between correlations is statistically significant if  it is greater 
than two standard errors (1 divided by the square root of  
sample size). 
Construct validity
Factor analysis: Exploratory factor analysis using prin-
cipal components with varimax rotation was performed 
to evaluate the factor structure of  the Chinese (HK) 
CLDQ. The criterion for factor extraction was an eigen-
value greater than one. The highest factor loading was 
identified for each item. The scree plot was also used to 
determine the number of  factors.
Convergent validity: Construct validity was also tested 
by convergent validity determined by Spearman correla-
tions between corresponding CLDQ and SF-36v2 Health 
Survey domain scores. It was hypothesized that moderate 
(r = 0.4 to 0.7) to strong (r > 0.7) correlations should exist 
between CLDQ FA and SF-36v2 VT; between CLDQ SS 
and SF-36v2 BP; between CLDQ AC and SF-36v2 PF, RP 
and RE; and between CLDQ EF and SF-36v2 MH scores.
Sensitivity
The mean CLDQ scores were compared between two 
CHB patient groups, and the difference was tested by 
independent t to evaluate its sensitivity in detecting a dif-
ference between patients with complicated and uncompli-
cated infections. The sensitivity of  the CLDQ was also as-
sessed by the effect size (difference between group mean 
scores/overall standard deviation). According to Cohen[19], 
effect sizes of  0.3, 0.5 and 0.8 were considered small, me-
dium and large differences, respectively. An effect size of  
less than 0.3 was considered not significant.
Reliability
Different methods were used to assess reliability, including 
internal consistency and test-retest reliability. Internal 
consistency was measured by Cronbach’s α, which is a 
measure of  the extent to which items in a questionnaire 
are homogeneous (correlated) in supporting the same 
concept[20]. Test-retest reliability refers to the stability of  
an instrument over time[21], which was measured by the 
intra-class correlation (ICC) between the two-week test-
retest results. Reliability coefficients ≥ 0.7 and 0.9 are 
usually expected for group comparisons and individual 
comparisons, respectively[21].
RESULTS
Translational equivalence of the Chinese (HK) CLDQ
All items except item 11 (level of  energy) were found to 
be understood by 6 patients. Three out of  six patients did 
not understand item 11. Five patients (83%) interpreted 
the meaning of  all except four items (11, 13, 19 and 28) 
correctly. Four out of  six patients misinterpreted the 
meaning of  item 11 with three interpreting it as decreased 
physical strength. Two patients (33.3%) had difficulty in 
differentiating the meaning of  “sleepy” and “drowsy”; 
and did not seem to have interpreted the words “mood 
swings” (item 19). Two out of  six patients did not include 
the meaning of  “worried about never feeling better” (item 
28) in their interpretation. The Chinese (HK) translation 
was revised based on the results of  cognitive debriefing 
and the revised questionnaire was then field tested on 23 
CHB patients before this study. The final Chinese (HK) 
CLDQ was formed and its back-translation is shown in 
the appendix.
Subjects
One hundred and eighty four CHB patients were identi-
fied; 6 patients were excluded (3 had hepatitis B infection 
less than 6 mo, 2 had communication problems and 1 had 
co-infection with HCV) and 28 patients refused to partici-
pate in this study. One hundred and fifty Chinese adults 
consisting of  72 uncomplicated (normal liver function 
defined as liver enzymes persistently within the normal 
range and without any history of  cirrhosis or HCC) and 
78 complicated (cirrhosis or HCC) completed the study, 
giving a response rate of  84.3% (150/178). Table 1 shows 
their characteristics, overall and by disease severity groups. 
There were 8 patients in the complicated CHB group 
who had HCC without any cirrhosis and had normal liver 
function. There were no statistical differences in demo-
graphics between the uncomplicated and complicated 
CHB groups, except age and sex (P < 0.001). Complicated 
CHB patients were older and there were more men than 
those in the uncomplicated group which was expected 
because CHB complications were more common in men 
than in women and the median age for the development 
of  complications was 57.2 years[22,23].
Score distribution
Table 2 shows the distribution of  the Chinese (HK) 
CLDQ and SF-36v2 scores. There was practically no 
www.wjgnet.com
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floor effect but there were significant ceiling effects in 
the Chinese (HK) CLDQ AS, AC and WO subscales, 
more so in the uncomplicated than the complicated 
group. Significant ceiling effects were also found in 
most SF-36v2 Health Survey scales. Sub-group analysis 
showed that the mean Chinese (HK) CLDQ scores were 
significantly lower in the complicated group than the 
uncomplicated group in all subscale and overall scores.
Figure 1 compares the distribution of  the Chinese 
(HK) CLDQ scores with those from other countries. The 
distribution pattern of  the Chinese (HK) CLDQ subscale 
scores was very similar to those of  other countries[3,9,11,13], ex-
cept Italy, supporting cross-cultural conceptual equivalence. 
Scaling properties
Table 3 shows the mean item scores and standard deviation 
of  the 29 CLDQ items grouped under their hypothesized 
subscales. All correlations between items and their 
hypothesized subscales score exceeded the standard of  0.4.
All but six items had a higher correlation with its hy-
pothesized subscale than other subscales, i.e. 100% scaling 
success. Four items of  the SS subscale and two items of  
the AC subscale correlated more highly with some other 
subscales than their own. Scaling success was the lowest in 
item 3 “bodily pain”, which correlated more highly with 
four other subscales than with the SS subscale, with the 
highest found for EF, but the differences were not statisti-
cally significant. Items 6 “shortness of  breath”, 23 “dry 
mouth”, 27 “itching”, 7 “not able to eat as much as you 
would like” and 9 “trouble in lifting or carrying heavy ob-
jects” correlated higher with one to three other subscales 
than its own, but the differences in the correlations were 
not statistically significant.
The overall scaling success rate on discriminant validity 
was 100% for four scales (AS, FA, EF and WO), but it was 
73% for the AC subscale and 64% for the SS subscale.
Factor analysis
Table 4 illustrates the rotated factor loadings between the 
www.wjgnet.com
Table 1  Socio-demographic and clinical characteristics of subjects   n  (%)
Uncomplicated CHB (n  = 72) Complicated CHB (n  = 78) Overall (n  = 150)
Age, mean years ± SD1 50.2 ± 12.0 55.9 ± 9.5 53.2 ± 11.1
Sex1
Male 42  (58.3) 65  (83.3) 107  (71.3)
Female 30  (41.7) 13  (16.7)   43  (28.7)
Education attainment
No schooling   2  (2.8)   6  (7.7)     8  (5.3)
Primary 19  (26.4) 14  (17.9)   33  (22.0)
Secondary 35  (48.6) 46  (59.0)   81  (54.0)
Tertiary 16  (22.2) 12  (15.4)   28  (18.7)
Marital status
Now married, living with spouse 59  (81.9) 67  (85.9) 126  (84.0)
Never married   6  (8.3)   5  (6.4)   11  (7.3)
Widowed   1  (1.4)   1  (1.3)     2  (1.3)
Divorced/separated   6  (8.3)   5  (6.4)   11  (7.3)
Occupation
Managers, administrators & professional 19  (26.4) 17  (21.8)   36  (24.0)
Clerk, service and shop sales workers 16  (22.2) 19  (24.4)   35  (23.3)
Craft, machine operators & elementary 27  (37.5) 39  (50.0)   66  (44.0)
Others 10  (13.9)   3  (3.8)   13  (8.7)
Health status
CHB 72  (100)   72  (48.0)
Cirrhosis 30  (38.5)   30  (20.0)
HCC 48  (61.5)   48  (32.0)
Child-Pugh Classification
No cirrhosis/normal LF 72  (100)   8  (10.3)   80  (53.3)
Child A 47  (60.3)   47  (31.3)
Child B   8  (10.3)     8  (5.3)
Child C 15  (19.2)   15  (10.0)
CHB: Chronic hepatitis B; HCC: Hepatocellular carcinoma; LF: Liver function. Data are no. (%) of patients, unless otherwise indicated. 
1Significant difference between uncomplicated and complicated CHB groups by independent sample t or Fisher’s exact test, P < 0.05. Socio-
demographic variables are recoded as binary categorical variables for performing Fisher’s exact test: male vs female; no schooling vs any formal 
education; living with spouse vs other marital status; managers, administrators and professional vs other occupations.
Figure 1  The Chinese (HK) CLDQ scores by countries. AS: Abdominal 
Symptoms; FA: Fatigue; SS: Systemic Symptoms; AC: Activity; EF: Emotional 
Function; WO: Worry.
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29 items and 6 factors with eigenvalue > 1. The six factors 
explained 70.1% of  total variance. The factor loadings of  
the items were not entirely consistent with the scaling hy-
pothesis. Items of  the FA and SS subscales, except bodily 
pain (item 3), decreased strength (item 8) and decreased 
energy (item 11), seemed to load on the same factor (factor 
3). Two FA subscale items (8 “decreased energy” and 11 
“decreased strength”) loaded more strongly on AC than 
its hypothesized factor. A new factor (factor 6) was found 
with the highest loading from two items assessing sleep 
(items 16 and 20). The items of  EF, WO, AS and AC sub-
scales loaded nicely on their hypothesized factors. 
Construct validity
Table 5 shows the correlations between the scores of  the 
CLDQ and SF-36v2 Health Survey. As hypothesized, 
moderate to strong correlations were found between 
CLDQ FA and SF-36v2 VT scores; and between CLDQ 
SS and the SF-36v2 BP scores. The CLDQ AC score 
correlated significantly with all SF-36v2 Health Survey 
domain scores and the strongest was found with the SF-
36v2 RP and SF scores. The CLDQ EF score correlated 
strongly not only with the SF-36v2 MH score but 
moderately with the SF-36v2 VT, RE, RP and GH scores.
Sensitivity
As shown in Table 2, the CLDQ overall and subscale 
mean scores were all significantly higher in the uncom-
plicated than the complicated CHB group. The effect 
sizes of  the group differences in the CLDQ scores all 
exceeded 0.4 (range 0.4-0.6). Only three of  the eight 
SF-36v2 domain scores (PF, RP and SF) and the PCS 
score detected a significant difference between the 
uncomplicated and the complicated groups. However, the 
greatest effect size difference between the two groups was 
found in the SF-36v2 RP score. 
Reliability
Across all subscales, the Cronbach’s α coefficients of  
the internal consistency reliability were higher than the 
recommended value of  0.7 (Table 5). ICC coefficients 
measuring the two-week test-retest reliability exceeded 
0.7 in all but the AS (0.58) and AC (0.66) subscales. The 
reliability coefficients were comparable to those of  the 
SF-36v2 Health Survey.
Table 5 also shows that the correlations (range 
0.50-0.87) between the CLDQ subscales were smaller 
than the subscale internal reliability coefficients for all 
subscales, showing that each subscale measures a distinct 
concept. The overall CLDQ scores correlated strongly 
with all CLDQ subscale scores.
DISCUSSION
The mean scores of  the CLDQ found in our population 
were generally higher than those found in other countries. 
This might be the result of  a sampling difference, in 
that over half  of  our subjects had uncomplicated CHB 
infection and most of  the other studies included patients 
with more serious diseases and patients with HCV who 
tend to have more impairment in HRQOL than patients 
with CHB infection[24]. The other reason for a difference in 
the absolute HRQOL scores between different populations 
is a difference in the sociocultural norms. A comparison 
www.wjgnet.com
Table 2  Distribution of the Chinese (HK) CLDQ and SF-36v2 Health Survey scores1
Uncomplicated CHB2 (n  = 72) Complicated CHB2 (n  = 78) Overall (n  = 150)
Mean (SD) % floor3 % ceiling4 Mean (SD) % floor % ceiling Mean (SD) % floor % ceiling ES5
CLDQ
AS   6.3 (1.0) 0.0 47.2   5.6 (1.5) 0.0 28.2   5.9 (1.3) 0.0 37.3  0.5a
FA   5.2 (1.1) 0.0   6.9   4.6 (1.5) 0.0   5.1   4.9 (1.4) 0.0   6.0  0.4a
SS   5.8 (1.0) 0.0 19.4   5.2 (1.2) 0.0   6.4   5.5 (1.2) 0.0 12.7  0.5a
AC   6.2 (1.1) 0.0 48.6   5.4 (1.6) 0.0 28.2   5.8 (1.4) 0.0 38.0  0.6a
EF   5.5 (1.0) 0.0   8.3   5.0 (1.4) 0.0   5.1   5.2 (1.3) 0.0   6.7  0.4a
WO   5.9 (1.3) 1.4 37.5   5.0 (1.7) 0.0 17.9   5.4 (1.6) 0.7 27.3  0.6a
Overall   5.8 (0.8) 0.0   0.0   5.1 (1.2) 0.0   1.3   5.4 (1.1) 0.0   0.7  0.6a
SF-36v2 Health survey (HK norm)
PF (90.6) 89.0   (14.7) 0.0 34.7  80.4b   (15.4) 0.0 10.3 84.5   (15.6) 0.0 22.0  0.5a
RP (90.2)  83.6b   (21.0) 0.0 45.8  63.9b   (29.4) 1.3 24.4 73.4   (27.4) 0.7 34.7  0.7a
BP (82.6)  72.6b   (23.0) 0.0 31.9  70.1b   (28.6) 1.3 38.5 71.3   (26.0) 0.7 35.3 0.1
GH (53.2) 53.8   (21.7) 0.0   0.0  46.9b   (25.6) 0.0   2.6 50.2   (24.0) 0.0   1.3 0.3
VT (60.2) 63.9   (19.8) 1.4   1.4 58.0   (26.5) 5.1   5.1 60.8   (23.6) 3.3   3.3 0.2
SF (92.4)  86.1b   (19.3) 0.0 48.6  71.6b   (29.0) 1.3 35.9 78.6   (25.8) 0.7 42.0  0.6a
RE (88.5)  80.4b   (19.8) 0.0 36.1  75.0b   (26.9) 0.0 33.3 77.6   (23.8) 0.0 34.7 0.2
MH (72.0) 73.6   (18.4) 0.0   5.6 70.4   (21.9) 0.0 11.5 72.0   (20.3) 0.0   8.7 0.2
PCS (50)  46.4b (9.9) 0.0   0.0  39.5b   (12.2) 0.0   0.0 42.8   (11.6) 0.0   0.0  0.6a 
MCS (50) 50.1   (10.4) 0.0   0.0 47.8   (13.9) 0.0   0.0 48.9   (12.3) 0.0   0.0 0.2
AS: Abdominal Symptoms; FA: Fatigue; SS: Systemic Symptoms; AC: Activity; EF: Emotional Function; WO: Worry; PF: Physical Functioning; RP: Role 
Physical; BP: Bodily Pain; GH: General Health; VT: Vitality; SF: Social Functioning; RE: Role Emotional; MH: Mental Health; PCS: Physical Component 
Summary; MCS: Mental Component Summary; ES: Effect Size. 1The Chinese (HK) CLDQ score range 1-7 and SF-36v2 score range 0-100; higher scores 
indicate better health-related quality of life; 2Uncomplicated CHB are patients who had no cirrhosis or hepatocellular carcinoma (HCC) and normal liver 
function; Complicated CHB refers to those with cirrhosis or HCC; 3% floor: Percentage of CHB patients at the lowest possible score; 4% ceiling: Percentage 
of CHB patients at the highest possible score; 5Effect size was calculated as the difference between uncomplicated and complicated mean score, divided by 
the overall SD. aSignificant difference between uncomplicated and complicated CHB patients by independent sample t (P < 0.05); bSignificant difference 
between CHB groups and HK norm by independent sample t (P < 0.05).
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with the population norms of  generic HRQOL measures 
such as those of  the SF-36 Health Survey will provide a 
more meaningful interpretation on the impact of  CHB 
on HRQOL between different populations. Our study 
found that uncomplicated CHB patients had significant 
impairment in the SF-36v2 RP, BP, SF and RE domains, 
and complicated CHB patients had significantly lower SF-
36v2 scores in six domains (PF, RP, BP, GH, SF and RE) 
than the norms of  the HK population (Table 2)[25,26]. The 
findings suggested that CHB infection affected HRQOL 
only modestly unless complications develop. Surprisingly, 
there was no difference in the MH score between CHB 
patients and the HK population norm. It was unlikely 
that a potentially lethal chronic infection had no effect on 
mental health, the SF-36v2 Health Survey was probably 
not sensitive enough to detect the difference.
The high ceiling effects in the AS, AC and WO 
subscales in patients with uncomplicated CHB were 
expected since they were usually asymptomatic. A pattern 
that was similar to that found in a Spanish population[9]. 
A high ceiling effect was also observed among patients 
with complicated CHB which was unexpected, this was 
probably because most of  our subjects with complicated 
CHB were under anti-viral treatment that might have 
improved their HRQOL, or perhaps some patients had 
adjusted to their illnesses. On the whole, the CLDQ had 
a lower ceiling effect than the SF-36v2 Health Survey, 
suggesting that this disease-specific HRQOL measure 
would be more responsive than the generic measure in 
detecting improvements with treatment, which needs to 
be confirmed by prospective studies. The lack of  floor 
effect indicates that the Chinese (HK) CLDQ would be 
able to capture any deterioration in patients’ QOL as the 
disease progresses.
The item-subscale correlations and factor analysis re-
sults supported the scaling structure of  the Chinese (HK) 
www.wjgnet.com
Table 3  Item descriptive statistics and item-subscale correlations of the Chinese (HK) CLDQ
Item-subscale correlations1
Items Mean (SD) AS FA SS AC EF WO Success2 (%)
AS
1: Abdominal bloating 5.7 (1.6)  0.571 0.48 0.45 0.44 0.52 0.49 100
5: Abdominal pain 6.1 (1.4)  0.631 0.45 0.47 0.37 0.49 0.39 100
17: Abdominal discomfort 6.0 (1.5)  0.731 0.49 0.52 0.50 0.52 0.50 100
(100)
FA
2: Tiredness or fatigue 4.3 (1.6) 0.52  0.791 0.68 0.57 0.61 0.48 100
4: Feel sleepy during the day 4.4 (1.6) 0.35  0.701 0.55 0.45 0.49 0.36 100
8: Decreased strength 5.6 (1.7) 0.53  0.721 0.59 0.70 0.63 0.53 100
11: Decreased energy 5.0 (1.6) 0.40  0.771 0.59 0.61 0.66 0.47 100
13: Drowsiness 5.1 (1.7) 0.40  0.661 0.56 0.46 0.58 0.47 100
(100)
SS
3: Bodily pain 5.5 (1.7)  0.513  0.533  0.441 0.443  0.603 0.40 20
6: Shortness of breath 6.0 (1.5) 0.51  0.603  0.571 0.54 0.55 0.50 80
21: Muscle cramps 5.9 (1.4) 0.29 0.47  0.521 0.38 0.37 0.28 100
23: Dry mouth 4.7 (1.8) 0.37  0.473  0.471 0.41  0.513  0.543 40
27: Itching 5.4 (1.7) 0.30  0.493  0.491 0.41 0.42 0.41 80
(64)
AC
7: Not able to eat as much as you would like 5.6 (1.9) 0.42  0.593 0.46 0.561 0.48 0.47 80
9: Trouble in lifting or carrying heavy objects 5.8 (1.7) 0.40  0.513  0.553 0.421  0.523 0.40 40
14: Bothered by a limitation of the diet 6.0 (1.6) 0.37 0.47 0.44 0.651 0.50 0.50 100
(73)
EF
10: Anxiety 5.1 (1.8) 0.54 0.57 0.53 0.46  0.741 0.61 100
12: Unhappiness 5.2 (1.6) 0.43 0.58 0.52 0.44  0.721 0.52 100
15: Irritability 5.4 (1.5) 0.47 0.54 0.52 0.44  0.731 0.56 100
16: Difficulty in sleeping at night 5.1 (1.7) 0.45 0.46 0.46 0.45  0.591 0.48 100
19: Mood swings 5.5 (1.5) 0.46 0.60 0.57 0.50  0.791 0.54 100
20: Difficulty in falling asleep at night 4.5 (2.0 0.36 0.49 0.50 0.45  0.521 0.41 100
24: Depression 5.5 (1.4) 0.42 0.56 0.52 0.41  0.761 0.60 100
26: Problems with concentration 5.4 (1.6) 0.44 0.69 0.61 0.61  0.691 0.61 100
(100)
WO
18: Worries about the impact of the liver disease 5.5 (1.8) 0.56 0.49 0.44 0.50 0.64  0.641 100
22: Worries that symptoms will develop into major problem 5.1 (1.8) 0.43 0.42 0.45 0.37 0.52  0.791 100
25: Worries that the condition is getting worse 5.2 (1.8) 0.44 0.49 0.54 0.49 0.59  0.851 100
28: Worries about never feeling any better 5.6 (1.7) 0.44 0.54 0.57 0.59 0.67  0.831 100
29: Availability of a liver for transplant 5.7 (2.0) 0.36 0.45 0.47 0.55 0.48  0.621 100
(100)
1Spearman correlation between item and its hypothesized subscale corrected for overlap (relevant item removed from its subscale for correlation); 2Level of 
scaling success, item-subscale correlation is higher for hypothesized subscale than competing subscale; 3Item-subscale correlation is lower for hypothesized 
subscale than for competing subscale, but not statistically significant at the cutoff point of two standard errors (0.16).
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CLDQ in general. However, the scaling success rates of  
items 3 (bodily pain), 23 (dry mouth) and 9 (trouble in 
lifting or carrying heavy objects) seemed too low to be 
acceptable, raising the question whether they should be 
www.wjgnet.com
Table 4  Factor loadings of the Chinese (HK) CLDQ
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6
Item EF WO SS + FA AS AC SL
Abdominal symptom (AS)
1: Abdominal bloating 0.18  0.27 0.16  0.70 0.14  0.15
5: Abdominal pain 0.20  0.06 0.13  0.81 0.08  0.14
17: Abdominal discomfort 0.17  0.23 0.17  0.82 0.20  0.08
Fatigue (FA)
2: Tiredness or fatigue 0.33  0.03 0.51  0.31 0.45  0.22
4: Feel sleepy during the day 0.28 -0.05 0.47  0.14 0.44  0.14
8: Decreased strength 0.37  0.14 0.37  0.24 0.60  0.24
11: Decreased energy 0.56  0.06 0.37  0.11 0.51  0.12
13: Drowsiness 0.49  0.09 0.47  0.15 0.36 -0.17
Systemic symptoms (SS)
3: Bodily pain 0.49  0.00 0.18  0.39 0.14  0.22
6: Shortness of breath 0.22  0.22 0.59  0.39 0.18  0.03
21: Muscle cramps 0.09  0.08 0.76  0.17 0.10  0.14
23: Dry mouth 0.24  0.42 0.48  0.16 0.08 -0.02
27: Itching 0.10  0.27 0.65 -0.01 0.02  0.28
Activity (AC)
7: Not able to eat as much as you would like 0.05  0.29 0.04  0.24 0.81  0.12
9: Trouble in lifting or carrying heavy objects 0.41  0.18 0.37 -0.05 0.35  0.17
14: Bothered by a limitation of the diet 0.11  0.43 0.09  0.10 0.67  0.12
Emotional function (EF)
10: Anxiety 0.67  0.32 0.15  0.39 0.14  0.04
12: Unhappiness 0.77  0.25 0.15  0.20 0.13  0.01
15: Irritability 0.78  0.27 0.15  0.17 0.06  0.13
16: Difficulty in sleeping at night 0.27  0.17 0.17  0.18 0.14  0.79
19: Mood swings 0.78  0.24 0.10  0.19 0.20  0.21
20: Difficulty in falling asleep at night 0.16  0.14 0.25  0.22 0.25  0.71
24: Depression 0.8  0.31 0.15  0.08 0.03  0.22
26: Problems with concentration 0.52  0.28 0.29  0.18 0.37  0.27
Worry (WO)
18: Worries about the impact of the liver disease 0.40  0.47 0.03  0.50 0.25  0.07
22: Worries that symptoms will develop into major problem 0.29  0.80 0.11  0.16 0.04  0.05
25: Worries that the condition is getting worse 0.29  0.84 0.13  0.17 0.17  0.09
28: Worries about never feeling any better 0.27  0.77 0.13  0.18 0.26  0.24
29: Availability of a liver for transplant 0.16  0.64 0.26  0.14 0.30  0.10
SL: Sleep.
Table 5  Reliability and correlations of the Chinese (HK) CLDQ and SF-36v2 health survey scores
AS FA SS AC EF WO Cronbach’s α ICC1
CLDQ
AS 0.84 0.58
FA 0.54 0.88 0.82
SS 0.54 0.72 0.74 0.86
AC 0.5.0 0.67 0.60 0.72 0.66
EF 0.58 0.72 0.68 0.61 0.90 0.86
WO 0.52 0.57 0.60 0.58 0.69 0.90 0.89
Overall 0.72 0.87 0.84 0.80 0.86 0.81 0.90 0.85
SF-36v2 Health Survey
PF 0.47 0.56 0.65 0.54 0.47 0.46 0.81 0.93
RP 0.56 0.72 0.70 0.67 0.60 0.62 0.91 0.90
BP 0.44 0.44 0.62 0.42 0.48 0.44 0.89 0.77
GH 0.46 0.66 0.56 0.57 0.60 0.62 0.82 0.89
VT 0.51 0.79 0.63 0.58 0.67 0.54 0.86 0.85
SF 0.44 0.56 0.52 0.60 0.58 0.52 0.88 0.54
RE 0.53 0.51 0.52 0.46 0.66 0.50 0.89 0.74
MH 0.41 0.58 0.49 0.49 0.78 0.61 0.84 0.89
1All analyses were performed with the total sample of 150 patients, except for the Intra-class Correlation Coefficient 
(ICC), which was based on the results from 46 uncomplicated CHB patients.
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grouped under other subscales than the originally hy-
pothesized. It is interesting to note that bodily pain cor-
related the most with the EF subscale score and loaded 
the strongest on the EF factor (Table 4). It is a common 
observation that emotional state has a strong influence on 
pain perception and vice versa. Although the items on dry 
mouth or trouble in lifting or carrying heavy objects cor-
related more strongly with other subscales than their own, 
they should probably remain in the hypothesized subscale 
because the differences in the item-subscale correlations 
were not significant and the item-hypothesized subscale 
correlations were greater than 0.4. Furthermore, the fac-
tor loading results were not consistent with the results 
of  the item-subscale correlations. The item “dry mouth” 
correlated most strongly with WO subscale score but the 
loading was the highest on the SS factor (0.48). The item 
“trouble in lifting or carrying heavy objects” correlated 
highest with the SS score but factor analysis showed that 
it loaded most strongly on the factor of  EF. 
The factor structure of  the Chinese (HK) CLDQ 
version was almost identical to the original CLDQ in 
four subscales (EF, WO, AS and AC). The new factor of  
Sleep found in our Chinese population was also found 
in the Spanish, Italian and German population[9,10,27]. 
CHB patients may have sleep difficulties due to reasons 
other than emotional problems, such as pain and other 
symptoms. The items of  the FA and SS subscales, except 
items 3, 8 and 11, loaded on one single factor since they 
all measure symptoms. Items 8 and 11 of  the FA subscale 
loaded on the AC factor. Factor analysis with promax 
rotation was also performed to cross-validate the factor 
structure obtained by the varimax rotation, and it showed 
similar results with a new factor assessing sleep and items 
of  the FA subscale loaded mostly on the AC factor instead 
of  a separate factor. 
An alternative scaling structure for the Chinese (HK) 
CLDQ based on the factor loading results could be 
formed. Items 16 (difficulty in sleeping) and 20 (difficulty 
in falling asleep at night) were grouped into a new Sleep 
subscale. Items 8 (decreased strength) and 11 (decreased 
energy) were grouped into the AC subscale. Items 2, 4 and 
13 of  the original FA subscale are grouped with items of  
the SS subscale to form the new SS subscale. Item 3 (bodily 
pain), although loaded most strongly and correlated the 
most with EF factor, remains in the SS subscale because 
this has better face validity. The psychometric properties 
of  the revised Chinese (HK) CLDQ subscales with re-
grouping of  the items are shown in Table 6. It can be 
seen that the new subscale structure greatly improves the 
scaling success rates of  the SS and AC items, although it 
reduces the success rate of  the EF subscale slightly. The 
new scaling structure also reduced the ceiling effects of  
the SS and AC subscales. Further studies are needed to 
determine whether the revised subscale structure will 
translate into better sensitivity and responsiveness in 
clinical applications. Until such data are available, the 
original subscale structure of  the CLDQ is recommended 
to allow better international comparability.
The expected correlations between the CLDQ and SF-
36v2 Health Survey domains were observed confirming 
convergent construct validity. The correlation with the SF-
36v2 RE domain was higher in the CLDQ EF than the AC 
subscale because conceptually the SF-36v2 RE measures 
the effect of  emotional problems on daily activities.
The CLDQ subscales of  AS and WO address 
domains that are not assessed by the generic measure (SF-
36v2 Health Survey) and detected significant differences 
between the two groups of  CHB patients. There were 
significant differences in the WO and EF subscales of  the 
CLDQ between the CHB groups although this was not 
found in most of  the mental-health related domains (RE, 
MH and MCS) of  the SF-36v2 Health Survey, suggesting 
that the Chinese (HK) CLDQ was more sensitive than 
the generic measure in detecting the emotional impact 
of  CHB. It is worth noting that although more domains 
in the CLDQ showed a significant difference between 
the complicated and uncomplicated CHB groups, the 
largest effect size difference was found in the SF-36v2 
RP domain indicating that a disease-specific measure may 
not always be more sensitive than a generic measure. The 
two types of  HRQOL measures should complement each 
other in the evaluation of  the HRQOL of  CHB patients.
Internal consistency and test-retest reliability were 
acceptable for all subscales. Test-retest reliability (ICC) of  
the AS subscale was relatively low (0.58) probably because 
these symptoms could fluctuate from day to day and 
pain intensity might vary noticeably in a relatively short 
period of  time. Reliability of  the CLDQ in our study 
was generally higher than those found in other studies 
(0.46-0.95)[9,12]. The SS subscale had very good test-retest 
reliability (ICC 0.86) in our population. The very low ICC 
(0.23) found in the US study was likely the result of  an 
inappropriately long retest interval of  six months[3].
Our study administered the Chinese (HK) CLDQ 
using an interviewer since our populations had a relatively 
low literacy level. The performance of  the instrument 
by self-completion will need to be confirmed by further 
studies. The responsiveness of  the Chinese (HK) CLDQ 
in detecting changes with disease progression or anti-viral 
treatment will also need to be determined.
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Table 6  Psychometric properties of the revised Chinese (HK) CLDQ subscales
Revised subscales Mean SD % floor % ceiling Scaling success Cronbach's α ICC
AS 5.9 1.3 0.0 37.3 100.0 0.84 0.58
SS + FA 5.2 1.1 0.0   4.7   95.0 0.84 0.88
AC 5.6 1.4 0.0 20.7   88.0 0.84 0.75
EF 5.3 1.3 0.0 12.0   93.3 0.92 0.87
WO 5.4 1.6 0.7 27.3 100.0 0.90 0.89
SL 4.8 1.7 1.3 17.3 100.0 0.78 0.79
Overall Scores 5.4 1.1 0.0   0.7 NA 0.89 0.85
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The Chinese (HK) CLDQ was validated in content 
and construct. It had satisfactory psychometric properties 
in terms of  factor structure, scaling assumption, construct 
validity, reliability and sensitivity in Southern Chinese 
patients with CHB infection. It was more sensitive than the 
SF-36v2 Health Survey in detecting the impact of  CHB 
on mental-health and symptom related HRQOL. The 
Chinese (HK) CLDQ should be applicable to all Cantonese-
speaking Chinese in HK and other parts of  Southern China. 
It is also likely to be applicable to the majority of  Chinese 
populations in Australia, North America, and Europe who 
are mostly emigrants from HK. There was good equivalence 
in the score distribution pattern across several cultures 
indicating that it can be used as a cross-cultural HRQOL 
measure in multiethnic populations or global studies. Some 
modifications of  the scaling structure of  the CLDQ may 
improve its psychometric properties for CHB patients, 
which need to be explored by further clinical studies.
Appendix: Back-translation of Chinese (HK) CLDQ
Original Wording Backward Translation
This questionnaire is designed to 
find out how you have been feeling 
during the last 2 wk.
The purpose of this questionnaire 
is to understand how you felt in the 
past 2 wk.
You will be asked about you 
symptoms related to your liver 
disease, how you have been affected 
in doing activities, and how your 
mood has been.
The questions are about the 
symptoms resulting from your liver 
illness and how these symptoms 
affect your participation in 
activities, and your emotions.
Please complete all of questions and 
select only one response for each 
question.
Please answer all questions. You 
can only choose one answer for 
each question.
1 How much of the time during the 
last 2 wk have you been troubled by 
a feeling of abdominal bloating?
1 In the past 2 wk, how much time 
you have been bothered by your 
bloating problem?
All of the time All the time
Most of the time Most of the time
A good bit of the time Quite Often
Some of the time Sometimes
A little of the time A Short Time
Hardly any of the time Hardly Any
None of the time Never
2 How much of the time have you 
been tired or fatigued during the last 
2 wk?
2 In the past 2 wk, how much time 
did you feel tired or exhausted?
3 How much of the time during 
the last 2 wk have you experienced 
bodily pain?
3 In the past 2 wk, how much time 
did your body ache?
4 How often during the last 2 wk 
have you felt sleepy during the day?
4 In the past 2 wk, how often did 
you feel sleepy during the daytime?
5 How much of the time during 
the last 2 wk have you experienced 
abdominal pain?
5 In the past 2 wk, how much time 
did you have abdominal pain?
6 How much of the time during the 
last 2 wk has shortness of breath 
been a problem for you in your daily 
activities?
6 In the past 2 wk, how much time 
were your daily activities affected 
by your shortness of breath?
7 How much of the time during the 
last 2 wk have you not been able to 
eat as much as you would like?
7 In the past 2 wk, how much time 
were you unable to eat as much as 
you want?
8 How much of the time in the last 
2 wk have you been bothered by 
having decreased strength?
8 In the past 2 wk, how much time 
have you been bothered by the 
decline in your physical energy?
9 How often during the last 2 wk 
have you had trouble lifting or 
carrying heavy objects?
9 In the past 2 wk, how often did 
you find it difficult when you were 
lifting or carrying heavy objects?
10 How often during the last 2 wk 
have you felt anxious? 
10 In the past 2 wk, how often did 
you feel anxious?
11 How often during the last 2 wk 
have you felt a decreased level of 
energy?
11 In the past 2 wk, how often 
did you find your energy level 
decreasing?
12 How much of the time during the 
last 2 wk have you felt unhappy?
12 In the past 2 wk, how much time 
did you feel unhappy?
13 How often during the last 2 wk 
have you felt drowsy?
13 In the past 2 wk, how often did 
you feel sleepy?
14 How much of the time during the 
last 2 wk have you been bothered by 
a limitation of your diet?
14 In the past 2 wk, how much time 
have you been bothered by your 
restricted diet?
15 How often during the last 2 wk 
have you been irritable?
15 In the past 2 wk, how often did 
you become irritable?
16 How much of the time during the 
last 2 wk have you had difficulty 
sleeping at night?
16 In the past 2 wk, how much time 
did you find it difficult to sleep at 
night?
17 How much of the time during the 
last 2 wk have you been troubled by 
a feeling of abdominal discomfort?
17 In the past 2 wk, how much time 
have you been bothered by your 
abdominal discomfort?
18 How much of the time during 
the last 2 wk have you been worried 
about the impact your liver disease 
has on your family?
18 In the past 2 wk, how much 
time did you worry that your liver 
illness will affect your family?
19 How much of the time during 
the last 2 wk have you had mood 
swings?
19 In the past 2 wk, how much time 
did your emotions fluctuate?
20 How much of the time during the 
last 2 wk have you been unable to 
fall asleep at night?
20 In the past 2 wk, how much 
time were you unable to sleep until 
sunrise?
21 How often during the last 2 wk 
have you had muscle cramps?
21 In the past 2 wk, how often did 
your muscle cramp?
22 How much of the time during 
the last 2 wk have you been worried 
that your symptoms will develop 
into major problems?
22 In the past 2 wk, how much time 
did you worry that your symptoms 
will become a serious problem?
23 How much of the time during the 
last 2 wk have you had a dry mouth?
23 In the past 2 wk, how much time 
did you have dry mouth?
24 How much of the time during the 
last 2 wk have you felt depressed?
24 In the past 2 wk, how much time 
did you feel depressed?
25 How much of the time during 
the last 2 wk have you been 
worried about your condition 
getting worse?
25 In the past 2 wk, how much time 
did you worry that your condition 
will deteriorate?
26 How much of the time during the 
last 2 wk have you had problems 
concentration?
26 In the past 2 wk, how much time 
did you find it hard to concentrate?
27 How much of the time have you 
been troubled by itching during the 
last 2 wk?
27 In the past 2 wk, how much 
time have you been bothered by 
itchiness?
28 How much of the time during 
the last 2 wk have you been worried 
about never feeling any better?
28 In the past 2 wk, how much time 
did you worry that your health 
condition will not improve?
29 How much of the time during the 
last 2 wk have you been concerned 
about the availability of a liver if you 
need a liver transplant?
29 In the past 2 wk, how much 
time have you worried that you 
could not get a liver if you have to 
undergo a liver transplant?
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Background
Chronic hepatitis B (CHB) virus infection remains a global problem and a public 
health threat. CHB patients may suffer or die from liver-related complications, posing 
a threat to both mental and physical health, leading to impairment of quality of life.
Research frontiers
Health-related quality of life (HRQOL) outcomes should supplement traditional 
clinical outcomes in the evaluation of the impact and the effectiveness of 
treatment for patients with CHB infection.
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Innovations and breakthroughs
The Chronic Liver Disease Questionnaire (CLDQ) had been applied mainly to 
patients with hepatitis C virus infection in Western countries. This study was 
the first to show that a Chinese (Hong Kong) translation of the CLDQ was valid, 
reliable and sensitive for Southern Chinese patients with CHB infection. The 
CLDQ can be applied to millions of Southern Chinese CHB patients to evaluate 
their HRQOL. Some modifications might further improve its validity, reliability 
and sensitivity.
Applications
The Chinese (Hong Kong) CLDQ can be used to evaluate the impact of CHB 
virus infection and assess the effectiveness of anti-viral drug treatments in 
Cantonese-speaking Southern Chinese. The CLDQ can be used as a cross-
cultural HRQOL measure in international studies that include Southern Chinese.
Terminology
CHB virus infection refers to those who are hepatitis B surface antigen-positive for 
more than six months. Validity is defined as the extent to which a test measures 
what it is intended to measure. Reliability refers to the consistency or stability of 
the measurement process across time, patients or observers. 
Peer review
The authors validated and tested the psychometric properties of a Southern 
Chinese translation of the CLDQ and determined that their questionnaire was 
valid, reliable, and sensitive for southern Chinese patients with hepatitis B virus 
infection. The study was well done and used appropriate methodology to validate 
and test the questionnaire.
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